{"id":367156,"date":"2025-09-01T11:31:22","date_gmt":"2025-09-01T11:31:22","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-enovis-corporation\/"},"modified":"2025-09-01T11:31:22","modified_gmt":"2025-09-01T11:31:22","slug":"how-to-buy-enovis-corporation","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/","title":{"rendered":"Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Enovis Corporation (ENOV) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334108,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-367156","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enovis Corporation (ENOV) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enovis Corporation (ENOV) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Enovis Corporation (ENOV) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin, mevcut fiyat trendlerini anlay\u0131n ve bu medikal teknoloji \u015firketinin 2025-2030 b\u00fcy\u00fcme i\u00e7in neden benzersiz f\u0131rsatlar sundu\u011funu ke\u015ffedin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Enovis Corporation (ENOV) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin, mevcut fiyat trendlerini anlay\u0131n ve bu medikal teknoloji \u015firketinin 2025-2030 b\u00fcy\u00fcme i\u00e7in neden benzersiz f\u0131rsatlar sundu\u011funu ke\u015ffedin."},"intro":"Art\u0131r\u0131lm\u0131\u015f ger\u00e7eklik ile ortopedik cerrahiyi devrim niteli\u011finde de\u011fi\u015ftiren bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Enovis Corporation, medikal teknoloji inovasyonunun \u00f6n saflar\u0131n\u0131 temsil ediyor. Cerrahlar\u0131n eklem protezlerini ger\u00e7ekle\u015ftirme \u015feklini de\u011fi\u015ftiren ARVIS\u00ae sistemleri ve spor hekimli\u011finden rejeneratif \u00e7\u00f6z\u00fcmlere uzanan portf\u00f6y\u00fc ile bu \u015firket milyonlarca hayat\u0131 etkilerken heyecan verici yat\u0131r\u0131m f\u0131rsatlar\u0131 yarat\u0131yor. ENOV'un neden dikkatinizi hak etti\u011fini ve b\u00fcy\u00fcme hikayelerinin bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim.","intro_source":{"label":"Intro","type":"text","formatted_value":"Art\u0131r\u0131lm\u0131\u015f ger\u00e7eklik ile ortopedik cerrahiyi devrim niteli\u011finde de\u011fi\u015ftiren bir \u015firkete yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? Enovis Corporation, medikal teknoloji inovasyonunun \u00f6n saflar\u0131n\u0131 temsil ediyor. Cerrahlar\u0131n eklem protezlerini ger\u00e7ekle\u015ftirme \u015feklini de\u011fi\u015ftiren ARVIS\u00ae sistemleri ve spor hekimli\u011finden rejeneratif \u00e7\u00f6z\u00fcmlere uzanan portf\u00f6y\u00fc ile bu \u015firket milyonlarca hayat\u0131 etkilerken heyecan verici yat\u0131r\u0131m f\u0131rsatlar\u0131 yarat\u0131yor. ENOV'un neden dikkatinizi hak etti\u011fini ve b\u00fcy\u00fcme hikayelerinin bir par\u00e7as\u0131 nas\u0131l olabilece\u011finizi ke\u015ffedelim."},"body_html":"<h2>\ud83d\udcc8 Mevcut Piyasa Konumu ve Giri\u015f Noktas\u0131<\/h2> <p>1 Eyl\u00fcl 2025 itibar\u0131yla Enovis Corporation (ENOV) hisseleri <strong>31,02 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, hissenin 52 haftal\u0131k 25,47 $ ile 49,83 $ aras\u0131ndaki aral\u0131\u011f\u0131 g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda \u00f6nemli bir f\u0131rsat sunuyor. Mevcut de\u011ferleme bu aral\u0131\u011f\u0131n alt s\u0131n\u0131r\u0131na yak\u0131n olup, \u00f6nemli bir y\u00fckseli\u015f potansiyeli yarat\u0131yor.<\/p> <p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131<\/strong>: Takviminize <strong>29 Ekim 2025<\/strong> tarihini i\u015faretleyin - Enovis'in bir sonraki kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu t\u00fcr olaylar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur. 7 A\u011fustos 2025'teki son kazan\u00e7 raporu, \u015firketin gelir tahminlerini 10,9 milyon $ a\u015fmas\u0131 ve d\u00fczeltilmi\u015f hisse ba\u015f\u0131 kazanc\u0131n\u0131n (EPS) 0,79 $ olarak beklentilerin 0,07 $ \u00fczerinde ger\u00e7ekle\u015fmesiyle etkileyici bir <strong>%11,94 \u00f6n piyasa rallisi<\/strong> tetiklemi\u015ftir.<\/p> <h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3> <p>Son performans desenlerine bak\u0131ld\u0131\u011f\u0131nda:<\/p> <ul> <li><strong>A\u011fustos 2025 2. \u00c7eyrek Kazan\u00e7lar\u0131<\/strong>: G\u00fc\u00e7l\u00fc sonu\u00e7larla hisse \u00f6n piyasada %11,94 y\u00fckseldi<\/li> <li><strong>May\u0131s 2025 1. \u00c7eyrek Raporu<\/strong>: %8 gelir art\u0131\u015f\u0131 olumlu momentum sa\u011flad\u0131<\/li> <li><strong>\u015eubat 2025 Y\u0131ll\u0131k Sonu\u00e7lar<\/strong>: \u015eirketin toparlanma yolunu g\u00f6sterdi<\/li> <\/ul> <p>Desen, Enovis'in 2025'te beklentileri s\u00fcrekli a\u015ft\u0131\u011f\u0131n\u0131 ve her kazan\u00e7 a\u00e7\u0131klamas\u0131n\u0131n uyan\u0131k yat\u0131r\u0131mc\u0131lar i\u00e7in al\u0131m f\u0131rsatlar\u0131 yaratt\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca Alt\u0131 Ayl\u0131k Performans Yolculu\u011fu<\/h2> <p>Enovis son alt\u0131 ayda olduk\u00e7a dalgal\u0131 bir seyir izledi. Hisse senedi y\u0131lba\u015f\u0131ndan bu yana yakla\u015f\u0131k <strong>%29-33 oran\u0131nda de\u011fer kaybetti<\/strong>, bu da 2025'i hissedarlar i\u00e7in zorlu bir d\u00f6nem haline getirdi. Ancak bu d\u00fc\u015f\u00fc\u015f\u00fcn ba\u011flam\u0131 \u00f6nemlidir:<\/p> <ul> <li><strong>Mart 2025<\/strong>: Daha geni\u015f piyasa bask\u0131lar\u0131 \u00f6ncesinde 40 $+ seviyelerinde i\u015flem g\u00f6rd\u00fc<\/li> <li><strong>May\u0131s 2025<\/strong>: 1. \u00e7eyrek kazan\u00e7lar\u0131 %8 b\u00fcy\u00fcme g\u00f6stererek ge\u00e7ici destek sa\u011flad\u0131<\/li> <li><strong>Temmuz 2025<\/strong>: Yaz d\u00fc\u015f\u00fc\u015fleri \u00f6ncesinde hisse 34,64 $ civar\u0131nda i\u015flem g\u00f6rd\u00fc<\/li> <li><strong>A\u011fustos 2025<\/strong>: G\u00fc\u00e7l\u00fc 2. \u00e7eyrek sonu\u00e7lar\u0131 diplerden toparlanma yaratt\u0131<\/li> <\/ul> <p>Genel d\u00fc\u015f\u00fc\u015fe ra\u011fmen, hisse son bir ayda <strong>%13-16 aras\u0131nda ayl\u0131k diren\u00e7 g\u00f6sterdi<\/strong>, bu da a\u015f\u0131r\u0131 sat\u0131m seviyelerine ula\u015ft\u0131ktan sonra potansiyel bir stabilizasyonu i\u015faret ediyor. \u00dc\u00e7 ayl\u0131k performans ise sadece %1,39 d\u00fc\u015f\u00fc\u015f g\u00f6stererek, zarar\u0131n \u00e7o\u011funun y\u0131l\u0131n ba\u015f\u0131nda ger\u00e7ekle\u015fti\u011fini ve son d\u00f6nemde g\u00f6receli bir istikrar oldu\u011funu g\u00f6steriyor.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Kapsaml\u0131 analist takibi ve \u015firket temellerine dayanarak, gelecekte neler olabilece\u011fi \u015f\u00f6yle:<\/p> <p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: Ortalama 45,62 $ (mevcut seviyelerden %47 y\u00fckseli\u015f potansiyeli)<\/p> <ul> <li>Eyl\u00fcl 2025: 50,08 $ projeksiyonu<\/li> <li>Ekim 2025: 47,42 $ beklentisi<\/li> <li>Kas\u0131m 2025: 43,70 $ tahmini<\/li> <li>Aral\u0131k 2025: 36,94 $ \u00f6ng\u00f6r\u00fcs\u00fc<\/li> <\/ul> <p><strong>2026 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 51-59 $ aral\u0131\u011f\u0131 (%65-90 potansiyel b\u00fcy\u00fcme)<br> Analistler \"G\u00fc\u00e7l\u00fc Al\" g\u00f6r\u00fc\u015f\u00fcn\u00fc koruyor ve ortalama fiyat hedefi 51,00 $ olup yakla\u015f\u0131k %65 y\u00fckseli\u015f potansiyeli sunuyor. En y\u00fcksek hedef Canaccord Genuity taraf\u0131ndan 75,00 $ olarak belirlenmi\u015ftir.<\/p> <p><strong>2028 Projeksiyonu<\/strong>: 60-75 $ aral\u0131\u011f\u0131 (%93-142 b\u00fcy\u00fcme potansiyeli)<br> ARVIS sistemi gibi yeni \u00fcr\u00fcn inovasyonlar\u0131n\u0131n daha geni\u015f benimsenmesi ve sat\u0131n alma sinerjilerinin ger\u00e7ekle\u015fmesiyle.<\/p> <p><strong>2030 Vizyonu<\/strong>: 75-100+ $ aral\u0131\u011f\u0131 (%142-222 uzun vadeli de\u011fer art\u0131\u015f\u0131)<br> Ya\u015flanan demografik yap\u0131lar, sa\u011fl\u0131kta teknolojik benimseme ve pazar pay\u0131 kazan\u0131mlar\u0131ndan faydalanacak \u015fekilde konumlanm\u0131\u015ft\u0131r.<\/p> <p><strong>Sonu\u00e7<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc AL. Mevcut de\u011ferleme, k\u0131sa vadeli zorluklar\u0131 indirgerken uzun vadeli b\u00fcy\u00fcme potansiyelini g\u00f6z ard\u0131 ediyor.<\/p> <h2>\u26a0\ufe0f Dikkate Al\u0131nmas\u0131 Gereken Yat\u0131r\u0131m Riskleri<\/h2> <p>Her yat\u0131r\u0131m risk ta\u015f\u0131r ve Enovis de istisna de\u011fildir:<\/p> <ul> <li><strong>Mali Performans Zorluklar\u0131<\/strong>: %23 gelir art\u0131\u015f\u0131na ra\u011fmen 2,1 milyar $ gelirle \u015firket 827 milyon $ net zarar bildirdi. Mevcut metrikler -14,64 EPS ve -41,37 milyon $ serbest nakit ak\u0131\u015f\u0131 negatif g\u00f6steriyor.<\/li> <li><strong>Y\u00fcksek Volatilite<\/strong>: 1,81 beta ile ENOV, genel piyasadan \u00e7ok daha volatil olup keskin fiyat dalgalanmalar\u0131na neden olabilir.<\/li> <li><strong>Sekt\u00f6r Rekabeti<\/strong>: Stryker, Zimmer Biomet ve DePuy Synthes gibi k\u00f6kl\u00fc devlerle rekabet ediyor ve medikal ekipman pazar\u0131nda sadece %2,4 pazar pay\u0131na sahip.<\/li> <li><strong>Y\u00f6nlendirme Revizyonlar\u0131<\/strong>: Tarifeler ve tedarik zinciri maliyetleri nedeniyle 2025 EBITDA rehberli\u011fi 405-415 milyon $ aral\u0131\u011f\u0131ndan 385-395 milyon $ aral\u0131\u011f\u0131na d\u00fc\u015f\u00fcr\u00fcld\u00fc.<\/li> <li><strong>Liderlik De\u011fi\u015fimi<\/strong>: Matt Trerotola'dan Damien McDonald'a CEO de\u011fi\u015fimi, kritik b\u00fcy\u00fcme a\u015famas\u0131nda y\u00fcr\u00fctme belirsizli\u011fi yarat\u0131yor.<\/li> <\/ul> <h2>\ud83d\udea6 2025 \u0130\u00e7in Pozitif Sinyaller<\/h2> <p>Risklere ra\u011fmen, yat\u0131r\u0131m i\u00e7in destekleyici birka\u00e7 \u00f6nemli fakt\u00f6r var:<\/p> <ul> <li><strong>G\u00fc\u00e7l\u00fc B\u00fcy\u00fcme Momentum<\/strong>: 2025 2. \u00e7eyrek geliri %7 art\u0131\u015fla 565 milyon $ oldu, tahminleri 10,9 milyon $ a\u015ft\u0131. Rekonstr\u00fcktif segment %11 b\u00fcy\u00fcme g\u00f6sterdi.<\/li> <li><strong>Analist G\u00fcveni<\/strong>: 17 analist hisseyi kaps\u0131yor ve oybirli\u011fiyle olumlu - 10 Al, 1 Tut, 0 Sat. Ortalama fiyat hedefi 51,00 $ olup %65 y\u00fckseli\u015f potansiyeli sunuyor.<\/li> <li><strong>Stratejik Sat\u0131n Almalar<\/strong>: 2025'in ilk yar\u0131s\u0131nda yedi sat\u0131n alma tamamland\u0131, b\u00fcy\u00fcmeyi h\u0131zland\u0131rd\u0131 ve teknolojik yetenekleri geni\u015fletti.<\/li> <li><strong>B\u00fcy\u00fck S\u00f6zle\u015fmeler<\/strong>: Ortopedik biyolojik \u00fcr\u00fcnler ve cerrahi implantlar i\u00e7in b\u00fcy\u00fck hastane a\u011flar\u0131yla \u00e7ok y\u0131ll\u0131 anla\u015fmalar sa\u011fland\u0131.<\/li> <li><strong>\u0130novasyon Liderli\u011fi<\/strong>: ARVIS art\u0131r\u0131lm\u0131\u015f ger\u00e7eklik sistemi, rekabet avantajlar\u0131yla yeni nesil cerrahi teknolojiyi temsil ediyor.<\/li> <li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Ya\u015flanan n\u00fcfus ve artan ortopedik prosed\u00fcr hacimleri uzun vadeli talep b\u00fcy\u00fcmesini destekliyor.<\/li> <\/ul> <h2>\ud83d\udcf0 \u00d6nemli Haber Etkisi Analizi<\/h2> <p>Son alt\u0131 ay Enovis i\u00e7in hareketli ge\u00e7ti:<\/p> <ul> <li><strong>2. \u00c7eyrek Kazan\u00e7 A\u015f\u0131m\u0131 (A\u011fustos 2025)<\/strong>: \u00d6ne \u00e7\u0131kan performans, hemen %11,94 \u00f6n piyasa kazanc\u0131 sa\u011flad\u0131. 565 milyon $ gelir (+%7 Y\/Y) ve 0,79 $ d\u00fczeltilmi\u015f EPS (+%27,4 Y\/Y) zorlu ko\u015fullara ra\u011fmen operasyonel m\u00fckemmelli\u011fi g\u00f6sterdi.<\/li> <li><strong>Liderlik De\u011fi\u015fimi (May\u0131s 2025)<\/strong>: Damien McDonald'\u0131n CEO olarak atanmas\u0131, Stryker deneyimi ve \"sermaye verimli y\u00fcr\u00fctme\" odakl\u0131 yakla\u015f\u0131m\u0131yla zamanla marjlar\u0131n iyile\u015fmesini sa\u011flayabilir.<\/li> <li><strong>\u00c7oklu Sat\u0131n Almalar<\/strong>: 2025'in ilk yar\u0131s\u0131nda yedi stratejik sat\u0131n alma \u00fcr\u00fcn portf\u00f6y\u00fcn\u00fc ve pazar eri\u015fimini geni\u015fletti, ancak entegrasyon riskleri devam ediyor.<\/li> <li><strong>Rehberlik Y\u00fckseltmesi<\/strong>: Y\u0131l sonu gelir rehberli\u011fi 2,245-2,275 milyar $ ve d\u00fczeltilmi\u015f EPS 3,05-3,20 $ olarak y\u00fckseltildi, y\u00f6netim g\u00fcvenini g\u00f6steriyor.<\/li> <\/ul> <p>T\u00fcccarlar i\u00e7in bu olaylar hem volatilite hem de f\u0131rsat yaratt\u0131. Kazan\u00e7 s\u00fcrprizleri genellikle anl\u0131k fiyat hareketleri \u00fcretirken, sat\u0131n alma haberleri entegrasyon ilerledik\u00e7e uzun vadeli etki yapar.<\/p> <h2>\ud83c\udfaf Yeni Ba\u015flayan T\u00fcccar Eylem Plan\u0131<\/h2> <p>Peki bug\u00fcn ne yapmal\u0131s\u0131n\u0131z? \u0130\u015fte profesyonel tavsiyem:<\/p> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n Ama Hemen Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5'inden fazlas\u0131n\u0131 temsil etmeyen bir pozisyonla ba\u015flay\u0131n. 52 haftal\u0131k diplere yak\u0131n mevcut de\u011ferleme cazip bir giri\u015f noktas\u0131 sunuyor.<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131 Yap\u0131n<\/strong>: Dip zamanlamas\u0131 yapmaya \u00e7al\u0131\u015fmak yerine, haftal\u0131k veya ayl\u0131k sabit tutarlarda yat\u0131r\u0131m yaparak giri\u015f fiyat\u0131n\u0131z\u0131 ortalay\u0131n.<\/li> <li><strong>Kazan\u00e7 Uyar\u0131lar\u0131 Ayarlay\u0131n<\/strong>: Takviminize 29 Ekim'i i\u015faretleyin. Tarihsel olarak, bu olaylar rapor sonras\u0131 d\u00fc\u015f\u00fc\u015flerde en iyi al\u0131m f\u0131rsatlar\u0131n\u0131 yarat\u0131r.<\/li> <li><strong>Uzun Vadeli D\u00fc\u015f\u00fcn\u00fcn<\/strong>: Bu h\u0131zl\u0131 bir al-sat i\u015flemi de\u011fil. Enovis, yeni teknolojiler benimsenirken ve sat\u0131n almalar meyve verirken sab\u0131r gerektirir.<\/li> <\/ol> <p><strong>Ve mizahi yorumum<\/strong>: \"ENOV ticareti ortopedik cerrahi gibidir - bazen uzun vadeli hareket kabiliyeti kazan\u0131mlar\u0131 i\u00e7in k\u0131sa vadeli ac\u0131ya katlanman\u0131z gerekir. Ama cerrahiyi kendiniz yapmaya \u00e7al\u0131\u015fmay\u0131n!\"<\/p> <h2>\u2705 Ad\u0131m Ad\u0131m: Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2> <table> <thead> <tr><th>Ad\u0131m<\/th><th>\u0130\u015flem<\/th><th>Neden \u00d6nemli<\/th><\/tr> <\/thead> <tbody> <tr><td>1<\/td><td>Platformunuzu Se\u00e7in<\/td><td>NYSE eri\u015fimi ve rekabet\u00e7i \u00fccretler sunan bir arac\u0131 kurum se\u00e7in<\/td><\/tr> <tr><td>2<\/td><td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td><td>Fonlar\u0131 g\u00fcvenli \u015fekilde transfer edin; riske atmaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td><\/tr> <tr><td>3<\/td><td>ENOV Aramas\u0131 Yap\u0131n<\/td><td>\"ENOV\" sembol\u00fcn\u00fc kullan\u0131n - sadece \"Enovis\" de\u011fil<\/td><\/tr> <tr><td>4<\/td><td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td><td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n; piyasa emirlerinden ka\u00e7\u0131n\u0131n<\/td><\/tr> <tr><td>5<\/td><td>\u0130nceleyin ve Onaylay\u0131n<\/td><td>Hisse adedi ve fiyat dahil emir detaylar\u0131n\u0131 \u00e7ift kontrol edin<\/td><\/tr> <tr><td>6<\/td><td>Pozisyonunuzu \u0130zleyin<\/td><td>Hem yukar\u0131 y\u00f6nl\u00fc hedefler hem de zarar durdurma seviyeleri i\u00e7in fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/td><\/tr> <tr><td>7<\/td><td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td><td>K\u00e2r alma seviyeleri ve risk y\u00f6netimi kurallar\u0131n\u0131 \u00f6nceden belirleyin<\/td><\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option Neden Mant\u0131kl\u0131<\/h2> <p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, ENOV gibi hisselerde pozisyon olu\u015fturmakla m\u00fckemmel uyumlu birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong>: Sadece 5 $ ile ba\u015flayarak stratejileri test edebilir ve pozisyonlar\u0131 kademeli olarak b\u00fcy\u00fctebilirsiniz, b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan.<\/li> <li><strong>H\u0131zl\u0131 Hesap Do\u011frulama<\/strong>: Tek bir belge ile 1 dakikal\u0131k KYC s\u00fcreci sayesinde karar verdikten hemen sonra i\u015flem yapmaya ba\u015flayabilirsiniz.<\/li> <li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: Kripto paralar, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100'den fazla \u00e7ekim y\u00f6ntemi esneklik sa\u011flar.<\/li> <li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: <a href=\"https:\/\/pocketoption.com\/blog\">Pocket Option blogu<\/a>, medikal teknoloji hisseleri ve piyasa trendlerini anlamak i\u00e7in de\u011ferli bilgiler sunar.<\/li> <\/ul> <p>Kazan\u00e7 a\u00e7\u0131klamalar\u0131 veya teknik k\u0131r\u0131lmalar etraf\u0131ndaki h\u0131zl\u0131 ticaret f\u0131rsatlar\u0131 i\u00e7in Pocket Option platformu, ENOV'un volatilitesinden yararlan\u0131rken risk y\u00f6netimi kontrollerini korumak i\u00e7in gereken tepki h\u0131z\u0131n\u0131 sa\u011flar.<\/p> <h2>\ud83c\udfe5 2025'te Enovis: Medikal Teknoloji Yenilik\u00e7isi<\/h2> <p>Enovis Corporation, medikal inovasyon ile hasta bak\u0131m\u0131n\u0131n iyile\u015ftirilmesinin kesi\u015fim noktas\u0131nda yer al\u0131r. \u015eirket, hasta sonu\u00e7lar\u0131n\u0131 iyile\u015ftiren ve ya\u015fam i\u00e7in hareketi geri kazand\u0131ran klinik olarak farkl\u0131la\u015ft\u0131r\u0131lm\u0131\u015f \u00e7\u00f6z\u00fcmler geli\u015ftirmeye odaklanan k\u00fcresel bir medikal teknoloji i\u015fletmesidir.<\/p> <p><strong>Mevcut Piyasa Konumu<\/strong>: 2,19 milyar $ son 12 ayl\u0131k gelirle Enovis, Stryker ve Zimmer Biomet gibi devlerle rekabet eden rekabet\u00e7i medikal cihaz alan\u0131nda faaliyet g\u00f6stermektedir. \u00dcr\u00fcn portf\u00f6y\u00fc rekonstr\u00fcktif eklem \u00fcr\u00fcnleri, spor hekimli\u011fi, g\u00fc\u00e7lendirilmi\u015f cerrahi aletler, destekleyici ortezler ve rejeneratif \u00e7\u00f6z\u00fcmleri kapsar.<\/p> <p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Enovis'in ARVIS\u00ae art\u0131r\u0131lm\u0131\u015f ger\u00e7eklik sistemi, cerrahlar\u0131n karma\u015f\u0131k eklem protezlerini ger\u00e7ek zamanl\u0131, eller serbest rehberlikle ger\u00e7ekle\u015ftirmesini sa\u011flayan \u00e7\u0131\u011f\u0131r a\u00e7an bir teknolojidir. Bu sistem, dijital navigasyonu do\u011frudan cerrah\u0131n g\u00f6r\u00fc\u015f alan\u0131na yans\u0131tarak ameliyat s\u0131ras\u0131nda \"X-\u0131\u015f\u0131n\u0131 g\u00f6r\u00fc\u015f\u00fc\" sa\u011flar ve cerrah\u0131n hastadan g\u00f6z\u00fcn\u00fc ay\u0131rmas\u0131na gerek kalmaz!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 Mevcut Piyasa Konumu ve Giri\u015f Noktas\u0131<\/h2>\n<p>1 Eyl\u00fcl 2025 itibar\u0131yla Enovis Corporation (ENOV) hisseleri <strong>31,02 $<\/strong> fiyatla i\u015flem g\u00f6r\u00fcyor. Bu fiyat, hissenin 52 haftal\u0131k 25,47 $ ile 49,83 $ aras\u0131ndaki aral\u0131\u011f\u0131 g\u00f6z \u00f6n\u00fcne al\u0131nd\u0131\u011f\u0131nda \u00f6nemli bir f\u0131rsat sunuyor. Mevcut de\u011ferleme bu aral\u0131\u011f\u0131n alt s\u0131n\u0131r\u0131na yak\u0131n olup, \u00f6nemli bir y\u00fckseli\u015f potansiyeli yarat\u0131yor.<\/p>\n<p><strong>\u00d6nemli Tarih Uyar\u0131s\u0131<\/strong>: Takviminize <strong>29 Ekim 2025<\/strong> tarihini i\u015faretleyin &#8211; Enovis&#8217;in bir sonraki kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 g\u00fcn. Tarihsel olarak, bu t\u00fcr olaylar \u00f6nemli fiyat hareketlerine neden olmu\u015ftur. 7 A\u011fustos 2025&#8217;teki son kazan\u00e7 raporu, \u015firketin gelir tahminlerini 10,9 milyon $ a\u015fmas\u0131 ve d\u00fczeltilmi\u015f hisse ba\u015f\u0131 kazanc\u0131n\u0131n (EPS) 0,79 $ olarak beklentilerin 0,07 $ \u00fczerinde ger\u00e7ekle\u015fmesiyle etkileyici bir <strong>%11,94 \u00f6n piyasa rallisi<\/strong> tetiklemi\u015ftir.<\/p>\n<h3>Tarihsel Kazan\u00e7 Etkisi Analizi<\/h3>\n<p>Son performans desenlerine bak\u0131ld\u0131\u011f\u0131nda:<\/p>\n<ul>\n<li><strong>A\u011fustos 2025 2. \u00c7eyrek Kazan\u00e7lar\u0131<\/strong>: G\u00fc\u00e7l\u00fc sonu\u00e7larla hisse \u00f6n piyasada %11,94 y\u00fckseldi<\/li>\n<li><strong>May\u0131s 2025 1. \u00c7eyrek Raporu<\/strong>: %8 gelir art\u0131\u015f\u0131 olumlu momentum sa\u011flad\u0131<\/li>\n<li><strong>\u015eubat 2025 Y\u0131ll\u0131k Sonu\u00e7lar<\/strong>: \u015eirketin toparlanma yolunu g\u00f6sterdi<\/li>\n<\/ul>\n<p>Desen, Enovis&#8217;in 2025&#8217;te beklentileri s\u00fcrekli a\u015ft\u0131\u011f\u0131n\u0131 ve her kazan\u00e7 a\u00e7\u0131klamas\u0131n\u0131n uyan\u0131k yat\u0131r\u0131mc\u0131lar i\u00e7in al\u0131m f\u0131rsatlar\u0131 yaratt\u0131\u011f\u0131n\u0131 g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca Alt\u0131 Ayl\u0131k Performans Yolculu\u011fu<\/h2>\n<p>Enovis son alt\u0131 ayda olduk\u00e7a dalgal\u0131 bir seyir izledi. Hisse senedi y\u0131lba\u015f\u0131ndan bu yana yakla\u015f\u0131k <strong>%29-33 oran\u0131nda de\u011fer kaybetti<\/strong>, bu da 2025&#8217;i hissedarlar i\u00e7in zorlu bir d\u00f6nem haline getirdi. Ancak bu d\u00fc\u015f\u00fc\u015f\u00fcn ba\u011flam\u0131 \u00f6nemlidir:<\/p>\n<ul>\n<li><strong>Mart 2025<\/strong>: Daha geni\u015f piyasa bask\u0131lar\u0131 \u00f6ncesinde 40 $+ seviyelerinde i\u015flem g\u00f6rd\u00fc<\/li>\n<li><strong>May\u0131s 2025<\/strong>: 1. \u00e7eyrek kazan\u00e7lar\u0131 %8 b\u00fcy\u00fcme g\u00f6stererek ge\u00e7ici destek sa\u011flad\u0131<\/li>\n<li><strong>Temmuz 2025<\/strong>: Yaz d\u00fc\u015f\u00fc\u015fleri \u00f6ncesinde hisse 34,64 $ civar\u0131nda i\u015flem g\u00f6rd\u00fc<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: G\u00fc\u00e7l\u00fc 2. \u00e7eyrek sonu\u00e7lar\u0131 diplerden toparlanma yaratt\u0131<\/li>\n<\/ul>\n<p>Genel d\u00fc\u015f\u00fc\u015fe ra\u011fmen, hisse son bir ayda <strong>%13-16 aras\u0131nda ayl\u0131k diren\u00e7 g\u00f6sterdi<\/strong>, bu da a\u015f\u0131r\u0131 sat\u0131m seviyelerine ula\u015ft\u0131ktan sonra potansiyel bir stabilizasyonu i\u015faret ediyor. \u00dc\u00e7 ayl\u0131k performans ise sadece %1,39 d\u00fc\u015f\u00fc\u015f g\u00f6stererek, zarar\u0131n \u00e7o\u011funun y\u0131l\u0131n ba\u015f\u0131nda ger\u00e7ekle\u015fti\u011fini ve son d\u00f6nemde g\u00f6receli bir istikrar oldu\u011funu g\u00f6steriyor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Kapsaml\u0131 analist takibi ve \u015firket temellerine dayanarak, gelecekte neler olabilece\u011fi \u015f\u00f6yle:<\/p>\n<p><strong>2025 Y\u0131l Sonu Hedefi<\/strong>: Ortalama 45,62 $ (mevcut seviyelerden %47 y\u00fckseli\u015f potansiyeli)<\/p>\n<ul>\n<li>Eyl\u00fcl 2025: 50,08 $ projeksiyonu<\/li>\n<li>Ekim 2025: 47,42 $ beklentisi<\/li>\n<li>Kas\u0131m 2025: 43,70 $ tahmini<\/li>\n<li>Aral\u0131k 2025: 36,94 $ \u00f6ng\u00f6r\u00fcs\u00fc<\/li>\n<\/ul>\n<p><strong>2026 G\u00f6r\u00fcn\u00fcm\u00fc<\/strong>: 51-59 $ aral\u0131\u011f\u0131 (%65-90 potansiyel b\u00fcy\u00fcme)<br \/> Analistler &#8220;G\u00fc\u00e7l\u00fc Al&#8221; g\u00f6r\u00fc\u015f\u00fcn\u00fc koruyor ve ortalama fiyat hedefi 51,00 $ olup yakla\u015f\u0131k %65 y\u00fckseli\u015f potansiyeli sunuyor. En y\u00fcksek hedef Canaccord Genuity taraf\u0131ndan 75,00 $ olarak belirlenmi\u015ftir.<\/p>\n<p><strong>2028 Projeksiyonu<\/strong>: 60-75 $ aral\u0131\u011f\u0131 (%93-142 b\u00fcy\u00fcme potansiyeli)<br \/> ARVIS sistemi gibi yeni \u00fcr\u00fcn inovasyonlar\u0131n\u0131n daha geni\u015f benimsenmesi ve sat\u0131n alma sinerjilerinin ger\u00e7ekle\u015fmesiyle.<\/p>\n<p><strong>2030 Vizyonu<\/strong>: 75-100+ $ aral\u0131\u011f\u0131 (%142-222 uzun vadeli de\u011fer art\u0131\u015f\u0131)<br \/> Ya\u015flanan demografik yap\u0131lar, sa\u011fl\u0131kta teknolojik benimseme ve pazar pay\u0131 kazan\u0131mlar\u0131ndan faydalanacak \u015fekilde konumlanm\u0131\u015ft\u0131r.<\/p>\n<p><strong>Sonu\u00e7<\/strong>: Uzun vadeli yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc AL. Mevcut de\u011ferleme, k\u0131sa vadeli zorluklar\u0131 indirgerken uzun vadeli b\u00fcy\u00fcme potansiyelini g\u00f6z ard\u0131 ediyor.<\/p>\n<h2>\u26a0\ufe0f Dikkate Al\u0131nmas\u0131 Gereken Yat\u0131r\u0131m Riskleri<\/h2>\n<p>Her yat\u0131r\u0131m risk ta\u015f\u0131r ve Enovis de istisna de\u011fildir:<\/p>\n<ul>\n<li><strong>Mali Performans Zorluklar\u0131<\/strong>: %23 gelir art\u0131\u015f\u0131na ra\u011fmen 2,1 milyar $ gelirle \u015firket 827 milyon $ net zarar bildirdi. Mevcut metrikler -14,64 EPS ve -41,37 milyon $ serbest nakit ak\u0131\u015f\u0131 negatif g\u00f6steriyor.<\/li>\n<li><strong>Y\u00fcksek Volatilite<\/strong>: 1,81 beta ile ENOV, genel piyasadan \u00e7ok daha volatil olup keskin fiyat dalgalanmalar\u0131na neden olabilir.<\/li>\n<li><strong>Sekt\u00f6r Rekabeti<\/strong>: Stryker, Zimmer Biomet ve DePuy Synthes gibi k\u00f6kl\u00fc devlerle rekabet ediyor ve medikal ekipman pazar\u0131nda sadece %2,4 pazar pay\u0131na sahip.<\/li>\n<li><strong>Y\u00f6nlendirme Revizyonlar\u0131<\/strong>: Tarifeler ve tedarik zinciri maliyetleri nedeniyle 2025 EBITDA rehberli\u011fi 405-415 milyon $ aral\u0131\u011f\u0131ndan 385-395 milyon $ aral\u0131\u011f\u0131na d\u00fc\u015f\u00fcr\u00fcld\u00fc.<\/li>\n<li><strong>Liderlik De\u011fi\u015fimi<\/strong>: Matt Trerotola&#8217;dan Damien McDonald&#8217;a CEO de\u011fi\u015fimi, kritik b\u00fcy\u00fcme a\u015famas\u0131nda y\u00fcr\u00fctme belirsizli\u011fi yarat\u0131yor.<\/li>\n<\/ul>\n<h2>\ud83d\udea6 2025 \u0130\u00e7in Pozitif Sinyaller<\/h2>\n<p>Risklere ra\u011fmen, yat\u0131r\u0131m i\u00e7in destekleyici birka\u00e7 \u00f6nemli fakt\u00f6r var:<\/p>\n<ul>\n<li><strong>G\u00fc\u00e7l\u00fc B\u00fcy\u00fcme Momentum<\/strong>: 2025 2. \u00e7eyrek geliri %7 art\u0131\u015fla 565 milyon $ oldu, tahminleri 10,9 milyon $ a\u015ft\u0131. Rekonstr\u00fcktif segment %11 b\u00fcy\u00fcme g\u00f6sterdi.<\/li>\n<li><strong>Analist G\u00fcveni<\/strong>: 17 analist hisseyi kaps\u0131yor ve oybirli\u011fiyle olumlu &#8211; 10 Al, 1 Tut, 0 Sat. Ortalama fiyat hedefi 51,00 $ olup %65 y\u00fckseli\u015f potansiyeli sunuyor.<\/li>\n<li><strong>Stratejik Sat\u0131n Almalar<\/strong>: 2025&#8217;in ilk yar\u0131s\u0131nda yedi sat\u0131n alma tamamland\u0131, b\u00fcy\u00fcmeyi h\u0131zland\u0131rd\u0131 ve teknolojik yetenekleri geni\u015fletti.<\/li>\n<li><strong>B\u00fcy\u00fck S\u00f6zle\u015fmeler<\/strong>: Ortopedik biyolojik \u00fcr\u00fcnler ve cerrahi implantlar i\u00e7in b\u00fcy\u00fck hastane a\u011flar\u0131yla \u00e7ok y\u0131ll\u0131 anla\u015fmalar sa\u011fland\u0131.<\/li>\n<li><strong>\u0130novasyon Liderli\u011fi<\/strong>: ARVIS art\u0131r\u0131lm\u0131\u015f ger\u00e7eklik sistemi, rekabet avantajlar\u0131yla yeni nesil cerrahi teknolojiyi temsil ediyor.<\/li>\n<li><strong>Sekt\u00f6r R\u00fczgarlar\u0131<\/strong>: Ya\u015flanan n\u00fcfus ve artan ortopedik prosed\u00fcr hacimleri uzun vadeli talep b\u00fcy\u00fcmesini destekliyor.<\/li>\n<\/ul>\n<h2>\ud83d\udcf0 \u00d6nemli Haber Etkisi Analizi<\/h2>\n<p>Son alt\u0131 ay Enovis i\u00e7in hareketli ge\u00e7ti:<\/p>\n<ul>\n<li><strong>2. \u00c7eyrek Kazan\u00e7 A\u015f\u0131m\u0131 (A\u011fustos 2025)<\/strong>: \u00d6ne \u00e7\u0131kan performans, hemen %11,94 \u00f6n piyasa kazanc\u0131 sa\u011flad\u0131. 565 milyon $ gelir (+%7 Y\/Y) ve 0,79 $ d\u00fczeltilmi\u015f EPS (+%27,4 Y\/Y) zorlu ko\u015fullara ra\u011fmen operasyonel m\u00fckemmelli\u011fi g\u00f6sterdi.<\/li>\n<li><strong>Liderlik De\u011fi\u015fimi (May\u0131s 2025)<\/strong>: Damien McDonald&#8217;\u0131n CEO olarak atanmas\u0131, Stryker deneyimi ve &#8220;sermaye verimli y\u00fcr\u00fctme&#8221; odakl\u0131 yakla\u015f\u0131m\u0131yla zamanla marjlar\u0131n iyile\u015fmesini sa\u011flayabilir.<\/li>\n<li><strong>\u00c7oklu Sat\u0131n Almalar<\/strong>: 2025&#8217;in ilk yar\u0131s\u0131nda yedi stratejik sat\u0131n alma \u00fcr\u00fcn portf\u00f6y\u00fcn\u00fc ve pazar eri\u015fimini geni\u015fletti, ancak entegrasyon riskleri devam ediyor.<\/li>\n<li><strong>Rehberlik Y\u00fckseltmesi<\/strong>: Y\u0131l sonu gelir rehberli\u011fi 2,245-2,275 milyar $ ve d\u00fczeltilmi\u015f EPS 3,05-3,20 $ olarak y\u00fckseltildi, y\u00f6netim g\u00fcvenini g\u00f6steriyor.<\/li>\n<\/ul>\n<p>T\u00fcccarlar i\u00e7in bu olaylar hem volatilite hem de f\u0131rsat yaratt\u0131. Kazan\u00e7 s\u00fcrprizleri genellikle anl\u0131k fiyat hareketleri \u00fcretirken, sat\u0131n alma haberleri entegrasyon ilerledik\u00e7e uzun vadeli etki yapar.<\/p>\n<h2>\ud83c\udfaf Yeni Ba\u015flayan T\u00fcccar Eylem Plan\u0131<\/h2>\n<p>Peki bug\u00fcn ne yapmal\u0131s\u0131n\u0131z? \u0130\u015fte profesyonel tavsiyem:<\/p>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n Ama Hemen Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %3-5&#8217;inden fazlas\u0131n\u0131 temsil etmeyen bir pozisyonla ba\u015flay\u0131n. 52 haftal\u0131k diplere yak\u0131n mevcut de\u011ferleme cazip bir giri\u015f noktas\u0131 sunuyor.<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131 Yap\u0131n<\/strong>: Dip zamanlamas\u0131 yapmaya \u00e7al\u0131\u015fmak yerine, haftal\u0131k veya ayl\u0131k sabit tutarlarda yat\u0131r\u0131m yaparak giri\u015f fiyat\u0131n\u0131z\u0131 ortalay\u0131n.<\/li>\n<li><strong>Kazan\u00e7 Uyar\u0131lar\u0131 Ayarlay\u0131n<\/strong>: Takviminize 29 Ekim&#8217;i i\u015faretleyin. Tarihsel olarak, bu olaylar rapor sonras\u0131 d\u00fc\u015f\u00fc\u015flerde en iyi al\u0131m f\u0131rsatlar\u0131n\u0131 yarat\u0131r.<\/li>\n<li><strong>Uzun Vadeli D\u00fc\u015f\u00fcn\u00fcn<\/strong>: Bu h\u0131zl\u0131 bir al-sat i\u015flemi de\u011fil. Enovis, yeni teknolojiler benimsenirken ve sat\u0131n almalar meyve verirken sab\u0131r gerektirir.<\/li>\n<\/ol>\n<p><strong>Ve mizahi yorumum<\/strong>: &#8220;ENOV ticareti ortopedik cerrahi gibidir &#8211; bazen uzun vadeli hareket kabiliyeti kazan\u0131mlar\u0131 i\u00e7in k\u0131sa vadeli ac\u0131ya katlanman\u0131z gerekir. Ama cerrahiyi kendiniz yapmaya \u00e7al\u0131\u015fmay\u0131n!&#8221;<\/p>\n<h2>\u2705 Ad\u0131m Ad\u0131m: Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r<\/h2>\n<table>\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Platformunuzu Se\u00e7in<\/td>\n<td>NYSE eri\u015fimi ve rekabet\u00e7i \u00fccretler sunan bir arac\u0131 kurum se\u00e7in<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Fonlamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Fonlar\u0131 g\u00fcvenli \u015fekilde transfer edin; riske atmaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>ENOV Aramas\u0131 Yap\u0131n<\/td>\n<td>&#8220;ENOV&#8221; sembol\u00fcn\u00fc kullan\u0131n &#8211; sadece &#8220;Enovis&#8221; de\u011fil<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n; piyasa emirlerinden ka\u00e7\u0131n\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Hisse adedi ve fiyat dahil emir detaylar\u0131n\u0131 \u00e7ift kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>Pozisyonunuzu \u0130zleyin<\/td>\n<td>Hem yukar\u0131 y\u00f6nl\u00fc hedefler hem de zarar durdurma seviyeleri i\u00e7in fiyat uyar\u0131lar\u0131 ayarlay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>\u00c7\u0131k\u0131\u015f Stratejinizi Planlay\u0131n<\/td>\n<td>K\u00e2r alma seviyeleri ve risk y\u00f6netimi kurallar\u0131n\u0131 \u00f6nceden belirleyin<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option Neden Mant\u0131kl\u0131<\/h2>\n<p>Yat\u0131r\u0131m yolculu\u011funa ba\u015flayanlar i\u00e7in Pocket Option, ENOV gibi hisselerde pozisyon olu\u015fturmakla m\u00fckemmel uyumlu birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>Minimum Para Yat\u0131rma Esnekli\u011fi<\/strong>: Sadece 5 $ ile ba\u015flayarak stratejileri test edebilir ve pozisyonlar\u0131 kademeli olarak b\u00fcy\u00fctebilirsiniz, b\u00fcy\u00fck sermaye taahh\u00fcd\u00fc olmadan.<\/li>\n<li><strong>H\u0131zl\u0131 Hesap Do\u011frulama<\/strong>: Tek bir belge ile 1 dakikal\u0131k KYC s\u00fcreci sayesinde karar verdikten hemen sonra i\u015flem yapmaya ba\u015flayabilirsiniz.<\/li>\n<li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: Kripto paralar, e-c\u00fczdanlar ve geleneksel bankac\u0131l\u0131k dahil 100&#8217;den fazla \u00e7ekim y\u00f6ntemi esneklik sa\u011flar.<\/li>\n<li><strong>E\u011fitim Kaynaklar\u0131<\/strong>: <a href=\"https:\/\/pocketoption.com\/blog\">Pocket Option blogu<\/a>, medikal teknoloji hisseleri ve piyasa trendlerini anlamak i\u00e7in de\u011ferli bilgiler sunar.<\/li>\n<\/ul>\n<p>Kazan\u00e7 a\u00e7\u0131klamalar\u0131 veya teknik k\u0131r\u0131lmalar etraf\u0131ndaki h\u0131zl\u0131 ticaret f\u0131rsatlar\u0131 i\u00e7in Pocket Option platformu, ENOV&#8217;un volatilitesinden yararlan\u0131rken risk y\u00f6netimi kontrollerini korumak i\u00e7in gereken tepki h\u0131z\u0131n\u0131 sa\u011flar.<\/p>\n<h2>\ud83c\udfe5 2025&#8217;te Enovis: Medikal Teknoloji Yenilik\u00e7isi<\/h2>\n<p>Enovis Corporation, medikal inovasyon ile hasta bak\u0131m\u0131n\u0131n iyile\u015ftirilmesinin kesi\u015fim noktas\u0131nda yer al\u0131r. \u015eirket, hasta sonu\u00e7lar\u0131n\u0131 iyile\u015ftiren ve ya\u015fam i\u00e7in hareketi geri kazand\u0131ran klinik olarak farkl\u0131la\u015ft\u0131r\u0131lm\u0131\u015f \u00e7\u00f6z\u00fcmler geli\u015ftirmeye odaklanan k\u00fcresel bir medikal teknoloji i\u015fletmesidir.<\/p>\n<p><strong>Mevcut Piyasa Konumu<\/strong>: 2,19 milyar $ son 12 ayl\u0131k gelirle Enovis, Stryker ve Zimmer Biomet gibi devlerle rekabet eden rekabet\u00e7i medikal cihaz alan\u0131nda faaliyet g\u00f6stermektedir. \u00dcr\u00fcn portf\u00f6y\u00fc rekonstr\u00fcktif eklem \u00fcr\u00fcnleri, spor hekimli\u011fi, g\u00fc\u00e7lendirilmi\u015f cerrahi aletler, destekleyici ortezler ve rejeneratif \u00e7\u00f6z\u00fcmleri kapsar.<\/p>\n<p><strong>2025 \u0130lgin\u00e7 Ger\u00e7ek<\/strong>: Enovis&#8217;in ARVIS\u00ae art\u0131r\u0131lm\u0131\u015f ger\u00e7eklik sistemi, cerrahlar\u0131n karma\u015f\u0131k eklem protezlerini ger\u00e7ek zamanl\u0131, eller serbest rehberlikle ger\u00e7ekle\u015ftirmesini sa\u011flayan \u00e7\u0131\u011f\u0131r a\u00e7an bir teknolojidir. Bu sistem, dijital navigasyonu do\u011frudan cerrah\u0131n g\u00f6r\u00fc\u015f alan\u0131na yans\u0131tarak ameliyat s\u0131ras\u0131nda &#8220;X-\u0131\u015f\u0131n\u0131 g\u00f6r\u00fc\u015f\u00fc&#8221; sa\u011flar ve cerrah\u0131n hastadan g\u00f6z\u00fcn\u00fc ay\u0131rmas\u0131na gerek kalmaz!<\/p>\n"},"faq":[{"question":"Enovis Corporation hisseleri nereden al\u0131nabilir?","answer":"Enovis Corporation hisseleri NYSE'de \"ENOV\" sembol\u00fc ile i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online yat\u0131r\u0131m platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"ENOV hisseleri i\u00e7in 2025 y\u0131l sonu fiyat hedefi nedir?","answer":"Analistlerin ortalama 2025 y\u0131l sonu fiyat hedefi 45,62 $ olup, bu mevcut fiyatlara g\u00f6re yakla\u015f\u0131k %47 y\u00fckseli\u015f potansiyeli sunmaktad\u0131r."},{"question":"Enovis Corporation'\u0131n ARVIS sistemi nedir?","answer":"ARVIS, art\u0131r\u0131lm\u0131\u015f ger\u00e7eklik teknolojisi kullanarak cerrahlar\u0131n eklem protezi ameliyatlar\u0131n\u0131 ger\u00e7ek zamanl\u0131 ve eller serbest \u015fekilde yapmalar\u0131n\u0131 sa\u011flayan yenilik\u00e7i bir sistemdir."},{"question":"Enovis hisseleri i\u00e7in yat\u0131r\u0131m riskleri nelerdir?","answer":"Yat\u0131r\u0131m riskleri aras\u0131nda y\u00fcksek volatilite, net zarar raporlar\u0131, sekt\u00f6r rekabeti, rehberlik revizyonlar\u0131 ve liderlik de\u011fi\u015fiklikleri bulunmaktad\u0131r."},{"question":"Yeni ba\u015flayanlar ENOV hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck bir pozisyonla ba\u015flay\u0131p dolar maliyet ortalamas\u0131 yaparak, kazan\u00e7 raporlar\u0131 i\u00e7in uyar\u0131lar ayarlayarak ve uzun vadeli d\u00fc\u015f\u00fcnerek yat\u0131r\u0131m yapmalar\u0131 \u00f6nerilir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"Enovis Corporation hisseleri nereden al\u0131nabilir?","answer":"Enovis Corporation hisseleri NYSE'de \"ENOV\" sembol\u00fc ile i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online yat\u0131r\u0131m platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"ENOV hisseleri i\u00e7in 2025 y\u0131l sonu fiyat hedefi nedir?","answer":"Analistlerin ortalama 2025 y\u0131l sonu fiyat hedefi 45,62 $ olup, bu mevcut fiyatlara g\u00f6re yakla\u015f\u0131k %47 y\u00fckseli\u015f potansiyeli sunmaktad\u0131r."},{"question":"Enovis Corporation'\u0131n ARVIS sistemi nedir?","answer":"ARVIS, art\u0131r\u0131lm\u0131\u015f ger\u00e7eklik teknolojisi kullanarak cerrahlar\u0131n eklem protezi ameliyatlar\u0131n\u0131 ger\u00e7ek zamanl\u0131 ve eller serbest \u015fekilde yapmalar\u0131n\u0131 sa\u011flayan yenilik\u00e7i bir sistemdir."},{"question":"Enovis hisseleri i\u00e7in yat\u0131r\u0131m riskleri nelerdir?","answer":"Yat\u0131r\u0131m riskleri aras\u0131nda y\u00fcksek volatilite, net zarar raporlar\u0131, sekt\u00f6r rekabeti, rehberlik revizyonlar\u0131 ve liderlik de\u011fi\u015fiklikleri bulunmaktad\u0131r."},{"question":"Yeni ba\u015flayanlar ENOV hisselerine nas\u0131l yat\u0131r\u0131m yapmal\u0131?","answer":"K\u00fc\u00e7\u00fck bir pozisyonla ba\u015flay\u0131p dolar maliyet ortalamas\u0131 yaparak, kazan\u00e7 raporlar\u0131 i\u00e7in uyar\u0131lar ayarlayarak ve uzun vadeli d\u00fc\u015f\u00fcnerek yat\u0131r\u0131m yapmalar\u0131 \u00f6nerilir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enovis Corporation (ENOV) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enovis Corporation (ENOV) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-09-01T11:31:22+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Enovis Corporation (ENOV) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-09-01T11:31:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/\",\"name\":\"Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enovis Corporation (ENOV) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"datePublished\":\"2025-09-01T11:31:22+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp\",\"width\":2560,\"height\":1429},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Enovis Corporation (ENOV) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enovis Corporation (ENOV) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/","og_locale":"tr_TR","og_type":"article","og_title":"Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enovis Corporation (ENOV) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/","og_site_name":"Pocket Option blog","article_published_time":"2025-09-01T11:31:22+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Enovis Corporation (ENOV) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-09-01T11:31:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/","name":"Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r - Enovis Corporation (ENOV) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","datePublished":"2025-09-01T11:31:22+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals14-scaled.webp","width":2560,"height":1429},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-enovis-corporation\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"Enovis Corporation (ENOV) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Enovis Corporation (ENOV) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":367157,"slug":"how-to-buy-enovis-corporation","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu Enovis Corporation (ENOV) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu Enovis Corporation (ENOV)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-enovis-corporation\/"},"pt_AA":{"locale":"pt_AA","id":367158,"slug":"how-to-buy-enovis-corporation","post_title":"Como comprar a\u00e7\u00f5es da Enovis Corporation (ENOV) - Investimento em a\u00e7\u00f5es da Enovis Corporation (ENOV)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-enovis-corporation\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/367156","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=367156"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/367156\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334108"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=367156"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=367156"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=367156"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}